# **Stock Update**

# Cigarette price hikes; Minimal impact on earnings


## **ITC**

Reco: Buy | CMP: Rs285


### Company details

Price target:	Rs347
Market cap:	Rs349,588 cr
52-week high/low:	Rs323/251
NSE volume: (No of shares)	119 lakh
BSE code:	500875
NSE code:	ITC
Sharekhan code:	ITC
Free float: (No of shares)	1,224.7 cr

#### **Shareholding pattern**



#### **Price chart**



#### **Price performance**

(%)	1m	3m	6m	<b>12</b> m
Absolute	3.1	2.6	-8.9	10.6
Relative to Sensex	3.5	0.9	-5.4	1.2

# **Key points**

- ITC hikes prices of lower-end cigarette brands: ITC has taken price hike in 20% of its cigarette portfolio by increasing the prices of Flake Excel by 11% to Rs. 60 (pack of 10 sticks), Bristol by 6.7% to Rs. 64 (pack of 10 sticks) and Capstan by 14.5% to Rs. 55 (pack of 10 sticks). Our calculation suggests that this selective price hike would result in average price hike of 2%. Further, year-to-date, the weighted average price increase stands at ~4%.
- Price hikes would have initial impact on sales volumes; Earnings impact would be minimal: The recent price hikes are undertaken in the lower end of the portfolio and will have an immediate negative impact on sales volume. Brands such as Capstan, Bristol and Flake Excel have very limited preference in urban markets but are largely sold in tier-II and tier-III towns. However, price hikes in these brands were taken after a long gap as there was no significant tax increase on cigarettes in recent times. Hence, we expect price hikes to get absorbed in the market over the next two quarters. Though the price hike would result in moderation in sales volume in the immediate term, it will have limited impact on FY2020 earnings (factored in a 1% decline in FY2020 and FY2021 earnings estimates). We expect price hikes to provide some cushioning to EBIT margins of the cigarette business in the backdrop of revenue mix shifting towards lowprice cigarettes (largely below 69mm).
  - Retain Buy due to discounted valuations: Sales volumes of ITC's cigarette business are expected to grow in mid-single digit in FY2019 in absence of any significant increase in its cigarette portfolio. However, sustenance of the same would depend upon the government's action in terms of tax hike on cigarette (especially after the elections). On the other hand, the noncigarette FMCG business is expected to post double-digit revenue growth with strong growth in categories such as biscuits, snacks and personal care products. Moreover, profitability of the business is expected to improve with the increase in the scale of business. The hotel business will continue to post better performance because of strong room demand, while the paperboard, paper and packaging business would see margin improvement due to product mix enrichment and higher realisation. ITC's

March 06, 2019 2

Sharekhan Stock Update

revenue and earnings are expected to report a CAGR of 12-14% over FY2018-FY2021. The stock continues to trade at a discounted valuation of 25x its FY2020E earnings, which is at 50%

discount to some of the large-cap stocks such has HUL. We maintain our Buy recommendation on the stock with an unchanged price target (PT) of Rs. 347.

Valuations (Standalone)

Rs cr

Particulars	FY2017	FY2018	FY2019E	FY2020E	FY2021E
Revenue	40,088.7	40,627.5	45,363.0	51,013.1	57,475.9
Net profit	10,200.9	10,397.5	12,062.7	13,707.9	15,402.8
OPM (%)	36.4	38.3	38.1	38.6	38.9
EPS (Rs.)	8.4	8.5	9.9	11.2	12.6
PE(x)	34.1	33.5	28.8	25.4	22.6
EV/EBITDA (x)	22.5	20.9	18.7	16.3	14.4
RoCE (%)	29.8	28.4	28.9	31.0	32.5
RoNW (%)	23.5	21.5	22.9	24.5	25.2

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

March 06, 2019 3



Know more about our products and services

## For Private Circulation only

**Disclaimer:** This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst has not dealt or traded directly or indirectly in securities of the company and that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst further certifies that neither he or its associates or his relatives has any direct or indirect financial interest nor have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report nor have any material conflict of interest nor has served as officer, director or employee or engaged in market making activity of the company. Further, the analyst has also not been a part of the team which has managed or co-managed the public offerings of the company and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Limited or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Compliance Officer: Mr. Joby John Meledan; Tel: 022-61150000; email id: compliance@sharekhan.com; For any queries or grievances kindly email igc@sharekhan.com or contact: myaccount@sharekhan.com

**Registered Office:** Sharekhan Limited, 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVLR, Opp. Kanjurmarg Railway Station, Kanjurmarg (East), Mumbai – 400042, Maharashtra. Tel: 022 - 61150000. Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669; Research Analyst: INH000006183;

Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com; Investment in securities market are subject to market risks, read all the related documents carefully before investing.